Literature DB >> 11095833

Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment.

.   

Abstract

Human papillomavirus (HPV) infection is the most common sexually transmitted viral disease worldwide. Low-risk types of HPV (eg, HPV-6 and HPV-11) are the causative agents of genital warts, whereas high-risk types (eg, HPV-16 and HPV-18) have been associated with anogenital cancer, particularly cervical cancer. Cervical cancer remains the second most common cancer in women worldwide. Recent advances have led to a better understanding of how HPV causes cancer on a molecular level and of the immunologic response to HPV. Methods to detect HPV infection have been improved, and a new treatment method for genital warts has been developed. The production of empty capsids of HPV done using recombinant technology has led to the development of serologic assays for HPV. The empty capsids are now the basis of clinical trials of vaccines to prevent HPV infection and disease.

Entities:  

Year:  2000        PMID: 11095833     DOI: 10.1007/s11908-000-0083-z

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  55 in total

Review 1.  Humoral immune response to human papillomavirus infection.

Authors:  J J Carter; D A Galloway
Journal:  Clin Dermatol       Date:  1997 Mar-Apr       Impact factor: 3.541

2.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

4.  Seroprevalence of human papillomavirus type 16 in pregnant women.

Authors:  M E Hagensee; J Slavinsky; C M Gaffga; J Suros; P Kissinger; D H Martin
Journal:  Obstet Gynecol       Date:  1999-11       Impact factor: 7.661

5.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

7.  Detection of human papillomavirus in archival tissues. Comparison of in situ hybridization and polymerase chain reaction.

Authors:  E R Unger; S D Vernon; D R Lee; D L Miller; W C Reeves
Journal:  J Histochem Cytochem       Date:  1998-04       Impact factor: 2.479

8.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids.

Authors:  K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Effect of HIV infection on the natural history of anal human papillomavirus infection.

Authors:  C W Critchlow; S E Hawes; J M Kuypers; G M Goldbaum; K K Holmes; C M Surawicz; N B Kiviat
Journal:  AIDS       Date:  1998-07-09       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.